CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2016—Rheonix has completed development and testing of a microfluidic system and assay to simultaneously detect host anti-HIV antibodies and viral RNA in a single specimen of saliva or blood. The company’s findings are outlined in a recent Journal of AIDS & Clinical Research article (Chen Z, et al. 2016;7[1]:540). The Rheonix system aims to improve HIV testing by detecting early, acute HIV infection and addressing the well-known “seroconversion window” when antibodies are not yet detectable, thus eliminating the need for multiple patient visits to health care providers. The assay is performed on the Rheonix CARD (chemistry and reagent device).
Rheonix, 607-257-1242